DataString Consulting Company Logo
DataString Consulting Company Logo
Pharmaceutical Contract Manufacturing Market
Home»Top Market Reports»Pharmaceutical Contract Manufacturing Market

Pharmaceutical Contract Manufacturing Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802221, Published - April 2025

Segmented in Service Type (API, Formulation Development, Finished Dosage Formulations, Packaging & Labeling), Drug Type (Small Molecule Drugs, Biologics, Hormonal Drugs, Controlled Release Drugs, Others), Drug Delivery Type, Therapeutic Area and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Pharmaceutical Contract Manufacturing
Market Outlook

The market, for Pharmaceutical contract manufacturing was estimated at $136.7 billion in 2024; and it is anticipated to increase to $224.3 billion by 2030 with projections indicating a growth to around $338.8 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 8.6% over the forecast period. The thriving pharmaceutical contract manufacturing sector continues to manifest its significance as an essential component of the larger healthcare industry. Imbued by key driving factors such as the requirement for specialized manufacturing facilities, cost efficiencies, focus on core competencies and the increasing need for scalable solutions, theindustry'songoing relevance is unquestionable. Furthermore, surges in drug development activities, the rising demand for generic pharmaceuticals, and the escalating need to comply with stringent regulatory standards are invariably motivating growth in this sector. Additionally, the complex processes involved in modern drug manufacturing have placed an increasing dependence on contract manufacturers, thus driving the rising adoption of their capabilities, infrastructure and expertise.


Pharmaceutical Contract Manufacturing stands at the heart of the drug production sector, offering a range of services including drug development, formulation, production, and packaging. The process encompasses manufacturing of active pharmaceutical ingredients (APIs), formulation of these APIs into final drug products, and detailed packaging for market sale. Major applications include the production of generic and patented drugs, bio-pharmaceuticals including vaccines, and increasingly, cell and gene therapies.


Market Size Forecast & Key Insights

2019
$136B2024
2029
$311B2034

Absolute Growth Opportunity = $175B

The Pharmaceutical Contract Manufacturing market is projected to grow from $136.7 billion in 2024 to $311 billion in 2034. This represents a CAGR of 8.6%, reflecting rising demand across Drug Development Services, Biologics Manufacturing and Clinical Trial Services.

The Pharmaceutical Contract Manufacturing market is set to add $175 billion between 2024 and 2034, with manufacturer targeting Biologics & Hormonal Drugs Drug Type projected to gain a larger market share.

With Increasing preference for outsourced production, and Regulatory compliance and quality control, Pharmaceutical Contract Manufacturing market to expand 128% between 2024 and 2034.

Opportunities in the Pharmaceutical Contract Manufacturing Market

Strategic Collaborations

Strategic partnerships offer an excellent growth for organizations involved in Pharmaceutical Contract Manufacturing. By effectively collaborating with pharmaceutical innovators and research institutions, contract manufacturers can gain access to scientific advancements, advanced manufacturing technology, and potential blockbuster drugs.

Leveraging Untapped Markets and Technological Transformations

Although the Pharmaceutical Contract Manufacturing sector is mature in many developed countries, there remain untapped, emerging markets with high growth potential. Countries such as India, China, and Southeast Asia present significant opportunities due to their growing economies, rising healthcare demands, and favourable government policies. Securing a robust presence in these untapped geographical territories could enrich the global dominance of Pharmaceutical Contract Manufacturing establishments.

Contract manufacturers have a golden to leverage technological advances to streamline their operations, increase manufacturing capacity, and enhance product quality. Pharmaceutical Contract Manufacturing stands on the cusp of a technological transformation with the introduction of Industry 4.0 practices such as digital manufacturing, automation, AI, and robotics. Adopting these trends can tremendously improve operational efficiency, driving growth in this sector.

Growth Opportunities in North America and Asia-Pacific

Asia Pacific Outlook

Asia-Pacific is emerging as a hotspot for Pharmaceutical Contract Manufacturing, with countries like India and China leading the charge. The region offers cost-effective solutions due to its low labor cost and well-developed manufacturing facilities. The intense competition among regional players such as WuXi AppTec, Takeda Pharmaceutical, and Jubilant Life Sciences is an important factor propelling market growth. Growing incidences of chronic diseases, booming biopharmaceutical sector, and favorable government initiatives promoting pharmaceutical manufacturing are key factors driving growth in this region.

North America Outlook

Pharmaceutical Contract Manufacturing continues to experience strong growth in North America, driven primarily by the development of sophisticated biopharmaceutical products and outsourcing by major pharma industries. The presence of advanced manufacturing facilities combined with stringent regulatory norms makes it a favorable hub for pharmaceutical contract manufacturing. The region is witnessing robust competition amongst leading contract manufacturers like Lonza, Catalent, and Thermo Fisher Scientific. Key drivers for growth include a rise in the demand for generic drugs, the burgeoning geriatric population, and increasing investment in R&D activities.

North America Outlook

Pharmaceutical Contract Manufacturing continues to experience strong growth in North America, driven primarily by the development of sophisticated biopharmaceutical products and outsourcing by major pharma industries. The presence of advanced manufacturing facilities combined with stringent regulatory norms makes it a favorable hub for pharmaceutical contract manufacturing. The region is witnessing robust competition amongst leading contract manufacturers like Lonza, Catalent, and Thermo Fisher Scientific. Key drivers for growth include a rise in the demand for generic drugs, the burgeoning geriatric population, and increasing investment in R&D activities.

Asia-Pacific Outlook

Asia-Pacific is emerging as a hotspot for Pharmaceutical Contract Manufacturing, with countries like India and China leading the charge. The region offers cost-effective solutions due to its low labor cost and well-developed manufacturing facilities. The intense competition among regional players such as WuXi AppTec, Takeda Pharmaceutical, and Jubilant Life Sciences is an important factor propelling market growth. Growing incidences of chronic diseases, booming biopharmaceutical sector, and favorable government initiatives promoting pharmaceutical manufacturing are key factors driving growth in this region.

Growth Opportunities in North America and Asia-Pacific

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., Germany, China, India, Japan are expected to grow at 6.3% to 9.0% CAGR

2

Emerging Markets : Thailand, Argentina, South Africa are expected to grow at 8.3% to 10.8% CAGR

Market Analysis Chart

The Pharmaceutical Contract Manufacturing Industry is currently experiencing substantial growth due to a number of significant drivers. Among these is the robust demand for generic drugs, driven by a global ageing population and increasing chronic diseases. The industry also stands to gain from innovative manufacturing technologies such as continuous manufacturing and high-throughput screening. Future potential is indicative in burgeoning areas such as plans for targeted therapeutics and personalized medicine. Balancing these drivers, however, are certain restraints on the industry.

Recent Developments and Technological Advancement

December 2024

Global pharmaceutical giant, Johnson & Johnson announced a significant expansion of their contract manufacturing operations in a bid to optimize production costs and better serve evolving market needs

November 2024

Teva Pharmaceuticals partnered with Catalent Inc., an established player in pharmaceutical contract manufacturing, to enhance production capabilities and strategically navigate supply-chain complexities

September 2024

Aurobindo Pharma Limited, an Indian pharmaceutical company, inked a deal with Pfizer Inc. for contract manufacturing, marking a strategic shift towards outsourced production to ensure flexible and efficient operations.

With the surge in demand for novel medical treatments, pharmaceutical contract manufacturing has rapidly become a key player within the global healthcare industry. This paradigm shift has primarily been driven by an escalating need for cost-efficient and high-quality pharmaceutical production practices. Recently, we have observed an upward trend in the outsourcing of pharmaceutical manufacturing processes to contract manufacturing organizations .

Impact of Industry Transitions on the Pharmaceutical Contract Manufacturing Market

As a core segment of the Pharmaceutical industry, the Pharmaceutical Contract Manufacturing market develops in line with broader industry shifts. Over recent years, transitions such as Emergence of Biologics and Globalization and Expanding Markets have redefined priorities across the Pharmaceutical sector, influencing how the Pharmaceutical Contract Manufacturing market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Emergence of Biologics:

The pharmaceutical contract manufacturing industry is undergoing significant transformation due to the rise of biologics. Previously, pharmaceutical manufacturing revolved around the production of small molecule drugs. However, with the advent of biotech revolution, biologics have taken center stage in contract manufacturing. These complex molecules, often termed as drugs of the future, hold immense potential in treating various diseases that have remained unresponsive to traditional small molecule drugs. Contract manufacturers specializing in biologics ranging from monoclonal antibodies to cell and gene therapies are on the rise, redefining the landscape of pharmaceutical contract manufacturing. This trend towards biologics is pushing contract manufacturers to invest in advanced technologies, thereby making the industry more sophisticated and innovative.

2

Globalization and Expanding Markets:

Another major transition taking place in the pharmaceutical contract manufacturing realm is the expansion into emerging markets. Traditionally, most companies have operated in the established markets of North America and Europe.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Pharmaceutical Contract Manufacturing market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Increasing Preference for Outsourced Production, and Technological Advancements in Drug Production

In recent times, pharmaceutical companies have also been migrating towards a more cost-efficient and flexible production model. This involves outsourcing their manufacturing operations to contract manufacturing organizations so they can also focus on their core competencies, such as drug development and marketing. This shift indicates a growth in preference for pharmaceutical contract manufacturing, spurred by the need to streamline operations and reduce overheads.
With the advent of advanced therapy medicinal products , personalized medicines, and the rising prevalence of rare diseases, pharmaceutical companies are also tasked with producing complex and highly specialized drugs. Pharmaceutical contract manufacturers who are also equipped with cutting-edge technology and expertise have also an edge in these sectors. This technological progress is also expected to drive the pharmaceutical contract manufacturing sector in the foreseeable future.
The pharmaceutical industry is also one of the most regulated sectors globally. Ensuring compliance with these regulations and maintaining high-quality standards becomes challenging, especially for smaller players. Therefore, these companies are also increasingly resorting to contract manufacturing to meet good manufacturing practices and stringent regulatory requirements. Pursuing contract manufacturing services means reliability in delivering high-quality product batches, and this trend will also only increase the demand for pharmaceutical contract manufacturing services.

Restraint: Stringent Regulatory Compliance

Pharmaceutical Contract Manufacturing faces a sizable roadblock in the form of robust regulatory standards. Its a heavily regulated industry, where agencies like the U. S Food and Drug Administration and the European Medicines Agency have set strict rules for quality control, manufacturing, and distribution processes. These regulatory environments can pose significant challenges, causing delay in production schedules and imposing financial burdens on pharmaceutical manufacturing contractors. This can inhibit the overall market growth by restricting the expansion and scalability of contract manufacturing organizations.

Challenge: Technological Constraints

Another significant impeding growth in the Pharmaceutical Contract Manufacturing market is the technological limitations. The industry, by its nature, necessitates cutting-edge technology. Lack of technological upgrades in manufacturing processes can lead to inefficient production, thus affecting the quality of pharmaceutical products. Further, not only many contract manufacturers have the necessary resources to invest in advanced technologies.

Supply Chain Landscape

Raw Material Suppliers

BASF

Dow Chemicals

API Manufacturing

Boehringer Ingelheim

Catalent Pharma

Formulation & Development
Patheon / Pfizer CentreOne
Manufacturing & Packaging
Teva Pharmaceuticals / Dr. Reddy's Laboratories
Raw Material Suppliers

BASF

Dow Chemicals

API Manufacturing

Boehringer Ingelheim

Catalent Pharma

Formulation & Development

Patheon

Pfizer CentreOne

Manufacturing & Packaging

Teva Pharmaceuticals

Dr. Reddy's Laboratories

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Contract Manufacturing Organizations (CMO)
Pharmaceutical Industry
Lonza Group AG
Expansion through strategic alliances and mergers & acquisitions
Biologic Manufacturing
Pharmaceutical/Biopharmaceutical Industry
Boehringer Ingelheim
Embracing technology and prioritizing Research and Development (R&D)
Active Pharmaceutical Ingredients (API) Manufacturing
Pharmaceutical/Chemical Industry
Dr. Reddys Laboratories Ltd.
Focusing on specialty sectors and proprietary products
Over-the-Counter (OTC) Drug Manufacturing
Pharmaceutical/Consumer Health Industry
Catalent, Inc.
Delivering optimal products by focusing on patient-centricity and versatility in manufacturing capabilities

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Pharmaceutical Contract Manufacturing market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Pharmaceutical Contract Manufacturing in Biologics Manufacturing, Clinical Trial Services and Drug Development Services

Biologics Manufacturing

Utilization of Pharmaceutical Contract Manufacturing is also observed in the production of biologics. Biologics are medicinal products derived from living organisms, requiring a highly specialized manufacturing process. Eli Lilly and Roche, global leaders in biopharmaceuticals, often rely on contract manufacturers for expertise and specialized facilities necessary for the production of monoclonal antibodies, vaccines, and biosimilars

Clinical Trial Services

Pharmaceutical Contract Manufacturing entities play a crucial role in providing clinical trial services. Their assistance in manufacturing and packaging trial material, maintaining regulatory compliance, and enhancing the speed to market is crucial for pharmaceutical companies. Prestigious firms like Johnson & Johnson and Merck frequently engage contract manufacturers to support clinical trials, enhance resource utilization, and streamline workflows.

Drug Development Services

Pharmaceutical Contract Manufacturing has emerged as a critical component in drug development services, with contract manufacturers assisting pharmaceutical companies in developing novel and complex therapeutics. They often deploy advanced technologies and follow stringent standards to ensure the efficacy, safety, and quality of the drugs. Prominent players like Pfizer and Novartis leverage Pharmaceutical Contract Manufacturing capabilities to accelerate their drug developmental process and to focus on their core competencies

Pharmaceutical Contract Manufacturing vs.
Substitutes: Performance and Positioning Analysis

Pharmaceutical Contract Manufacturing provides a cost-effective solution, streamlining drug development and production, a contrast to in-house manufacturing. Among alternatives, it stands out due to its scalability, expertise, and potential for considerable market growth. These Alternatives specially Healthcare Contract Development And Manufacturing Organization has experienced a rapid growth as detailed in our latest report.

Pharmaceutical Contract Manufacturing
  • Healthcare Contract Development And Manufacturing Organization
    High efficiency in bulk production, access to specialized expertise and advanced technology
    High initial investment costs, dependency on external manufacturers
    Cost-effectiveness, robust quality control systems
    Limited customization, dependency on third-party schedules

Pharmaceutical Contract Manufacturing vs.
Substitutes: Performance and Positioning Analysis

Pharmaceutical Contract Manufacturing

  • High efficiency in bulk production, access to specialized expertise and advanced technology
  • High initial investment costs, dependency on external manufacturers

Healthcare Contract Development And Manufacturing Organization / Biotechnology And Pharmaceutical Services

  • Cost-effectiveness, robust quality control systems
  • Limited customization, dependency on third-party schedules

Pharmaceutical Contract Manufacturing provides a cost-effective solution, streamlining drug development and production, a contrast to in-house manufacturing. Among alternatives, it stands out due to its scalability, expertise, and potential for considerable market growth. These Alternatives specially Healthcare Contract Development And Manufacturing Organization has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Pharmaceutical Contract Manufacturing market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Pharmaceutical Contract Manufacturing across API, Formulation Development, and Finished Dosage Formulations Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Catalent Inc., Recipharm AB, and Lonza Group Ltd. by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Suppliers, API Manufacturing, and Formulation & Development. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Pharmaceutical Contract Manufacturing segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Suppliers (BASF, Dow Chemicals), API Manufacturing (Boehringer Ingelheim, Catalent Pharma), and Formulation & Development. Our parallel substitute analysis examines Healthcare Contract Development And Manufacturing Organization and Biotechnology And Pharmaceutical Services, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Catalent Inc., Recipharm AB, and Lonza Group Ltd., analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Pharmaceutical Contract Manufacturing market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Pharmaceutical Contract Manufacturing Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 148 billion
Revenue Forecast in 2034USD 311 billion
Growth RateCAGR of 8.6% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024136 billion
Growth OpportunityUSD 175 billion
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD billion and Industry Statistics
Market Size 2024136 billion USD
Market Size 2027175 billion USD
Market Size 2029206 billion USD
Market Size 2030224 billion USD
Market Size 2034311 billion USD
Market Size 2035338 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredService Type, Drug Type, Drug Delivery Type, Therapeutic Area
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledCatalent Inc., Recipharm AB, Lonza Group Ltd., Evonik Industries AG, Almac Group, Famar Health Care Services, Boehringer Ingelheim International GmbH, Jubilant Life Sciences Ltd., Pfizer CentreOne, Saneca Pharma a.s., Siegfried AG and Wuxi AppTec Co. Ltd.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Pharmaceutical Contract Manufacturing Market Size, Opportunities & Strategic Insights, by Service Type

4.1API
4.2Formulation Development
4.3Finished Dosage Formulations
4.4Packaging & Labeling
Chapter 5

Pharmaceutical Contract Manufacturing Market Size, Opportunities & Strategic Insights, by Drug Type

5.1Small Molecule Drugs
5.2Biologics
5.3Hormonal Drugs
5.4Controlled Release Drugs
5.5Others
Chapter 6

Pharmaceutical Contract Manufacturing Market Size, Opportunities & Strategic Insights, by Drug Delivery Type

6.1Transdermal Drug Delivery
6.2Rectal Drug Delivery
6.3Microsphere-Based Delivery
6.4UHT Preservative-Free
6.5Biphasic Drug Delivery
6.6Vaginal Drug Delivery
Chapter 7

Pharmaceutical Contract Manufacturing Market Size, Opportunities & Strategic Insights, by Therapeutic Area

7.1Pain Management
7.2CNS Disorders
7.3Oncology
7.4Women’s Health
7.5Gastroenterology
7.6Others
Chapter 8

Pharmaceutical Contract Manufacturing Market, by Region

8.1North America Pharmaceutical Contract Manufacturing Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Pharmaceutical Contract Manufacturing Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Pharmaceutical Contract Manufacturing Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Pharmaceutical Contract Manufacturing Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Pharmaceutical Contract Manufacturing Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Pharmaceutical Contract Manufacturing Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Catalent Inc.
9.2.2Recipharm AB
9.2.3Lonza Group Ltd.
9.2.4Evonik Industries AG
9.2.5Almac Group
9.2.6Famar Health Care Services
9.2.7Boehringer Ingelheim International GmbH
9.2.8Jubilant Life Sciences Ltd.
9.2.9Pfizer CentreOne
9.2.10Saneca Pharma a.s.
9.2.11Siegfried AG
9.2.12Wuxi AppTec Co. Ltd.